Clinical Publications – Demonstrating Feasibility in other Prostate Disease States | Profound Medical

Demonstrating Feasibility in other Prostate Disease States

Benign Prostatic Hyperplasia (BPH), Relief of Lower Urinary Tract Symptoms (LUTS) (n=36)

Transurethral ultrasound ablation (TULSA) for benign prostatic obstruction: 12 months clinical outcomes

Anttinen et al, AUA 2023 Annual Meeting (abstract MP76-10), The Journal of Urology (2023)

MRI-guided transurethral ultrasound ablation for BPH: 12-month clinical outcomes of a phase I study

Viitala et al, British Journal of Urology International (2021)

Relief of lower urinary tract symptoms after MRI-guided transurethral ultrasound ablation (TULSA) for localized prostate cancer: Subgroup analyses in patients with concurrent cancer and benign prostatic hyperplasia

Elterman et al, Journal of Endourology (2020)

Radio-Recurrent Localized Prostate Cancer: Phase I Study of Salvage TULSA (n=34)

Salvage transurethral ultrasound ablation (TULSA) for localized radio-recurrent prostate cancer: 12-month safety and oncological outcomes

Anttinen et al, EAU 2023 Annual Congress (abstract A0965), The Journal of Urology (2023)

Safety and efficacy of MRI-guided transurethral ultrasound ablation for radiorecurrent prostate cancer in the presence of gold fiducial markers

Mäkelä et al, Acta Radiologica (2022)

Salvage MRI-guided TULSA for localized radio-recurrent prostate cancer: 12-month functional and oncological results

Anttinen et al, European Urology Open Science (2020)

Palliation of Symptomatic Locally Advanced Prostate Cancer: Phase I Study of Palliative TULSA (n=10)

Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer

Anttinen et al, Scandinavian Journal of Urology (2020)

Customized Ablation Plans in Clinical Trials (n=60)

12-month clinical outcomes of MRI-guided transurethral ultrasound ablation for localized prostate cancer

Yli-Pietilä et al, EAU 2023 Annual Congress (abstract A0996), European Urology (2023)

Randomized Controlled Trials (RCT)

Comparison of postoperative complications between focal ablation and radical prostatectomy for intermediate-risk prostate cancer: the FARP randomized control trial

Baco et al, AUA 2023 Annual Meeting (abstract MP73-15), The Journal of Urology (2023)

Clinical Consultation Guide

Optimal strategies for managing prostate-specific antigen recurrence after primary radiotherapy in prostate cancer: The Finnish Perspective

Seikkula et al, European Urology Focus (2023)

CAUTION: Products shown may not be approved for sale in all jurisdictions. Rx only device.
Contact us at info@profoundmedical.com for more information regarding the regulatory status of the device.

106734B

Quick Links

Careers & Training

Head Office

Profound Medical Corp.,
2400 Skymark Avenue,
Unit #6, Mississauga, ON L4W 5K5, Canada

T: 647.476.1350
F: 647.847.3739
info@profoundmedical.com